Vaxcyte, Inc. (PCVX)

NMS – Real vaqt narxi. Valyuta: USD

59.82

+0.60 (1.01%)

Bozor ochiq: Aug 12, 2026, 3:46 PM EDT

59.21

-0.01 (-0.02%)

Oldingi bozordan keyin: Aug 11, 2026, 7:59 PM EDT

05.08.2026

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027 Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose of VAX-31 Infant Phase 2 Dose-Finding Study Expected Either Sequentially or Together by End of First Half of 2027 Company Initiated Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults; Topline Data Expected in Second Half of 2027 Approximately $2.5 Billion in Cash, Cash Equivalents and Investments as of June 30, 2026 SAN CARLOS, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced financial results for the second quarter ended June 30, 2026, and provided a business update.

Videolar

No Data

There is no data to display

Press-relizlar

05.08.2026

Vaxcyte, Inc. (PCVX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Vaxcyte, Inc. (PCVX)

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

Videolar

No Data

Press-relizlar

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

Videolar

No Data

Press-relizlar

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

Search stocks

Vaxcyte, Inc. (PCVX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Vaxcyte, Inc. (PCVX)

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

Videolar

No Data

Press-relizlar

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

Videolar

No Data

Press-relizlar

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update